OHSU Rare Disease Research Consortium Symposium 2015: Difference between revisions

From OpenWetWare
Jump to navigationJump to search
(4 intermediate revisions by the same user not shown)
Line 30: Line 30:
|--
|--
| 6:20 to 6:30
| 6:20 to 6:30
| Laura Hays, Ph.D., Executive Director, Fanconi Anemia Research Fund  
| Laura Hays, Ph.D., Executive Director, [http://fanconi.org Fanconi Anemia Research Fund]
| Making a difference: the David Frohnmayer advocacy formula
| Making a difference: the David Frohnmayer advocacy formula
|--  
|--  
| 6:30 to 6:35
| 6:30 to 6:35
| Maureen Hoatlin
| [https://www.linkedin.com/in/hoatlin Maureen Hoatlin, Ph.D.,MBA]
| OHSU Rare Disease Consortium overview and objective of the symposium
| OHSU Rare Disease Consortium overview and objective of the symposium


Line 55: Line 55:
|--
|--
| 7:10 to 7:20
| 7:10 to 7:20
| Cary O. Harding, M.D.
| [http://www.ohsu.edu/xd/education/schools/school-of-medicine/departments/basic-science-departments/molecular-and-medical-genetics/people/primary-faculty/cary-harding.cfm Cary Harding, M.D.]
| Clinical Trials in inborn errrors of amino acid and fatty acid metabolism
| Clinical Trials in inborn errrors of amino acid and fatty acid metabolism
|--
|--
| 7:20 to 7:40
| 7:20 to 7:40
| David Ellison, M.D.
| [http://www.ohsu.edu/xd/health/services/providers/?personid=201 David Ellison, M.D.]
|  
|  
:Part 1: All about that Bass: rare gene mutations and human blood pressure variation.  
:Part 1: All about that Bass: rare gene mutations and human blood pressure variation.  
Line 69: Line 69:
|--
|--
|8:20 to 8:25
|8:20 to 8:25
|Maureen Hoatlin
|[https://www.linkedin.com/in/hoatlin Maureen Hoatlin, Ph.D, MBA]
|Final Remarks, Action items, organizing for the future
|Final Remarks, Action items, organizing for the future
|--
|--

Revision as of 21:13, 30 March 2015

Equipped with his five senses, man explores the universe around him and calls the adventure Science. ~Edwin Powell Hubble, The Nature of Science, 1954


April 7, 2015, from 4-8:30 pm at OHSU in the Joseph Vey Conference Center

11th Floor, Doernbecher Children’s Hospital
700 SW Campus Drive
Portland, OR 97239

General Info

Registration

Schedule

Time Presenter Title
3:30 pm Registration
4:00-5:00 Sekar Kathiresan, M.D. Leveraging human knockouts to understand risk for and protection from disease
5:00 to 6:10 Poster session and reception
6:10 to 6:20 Mary Stenzel-Poore, Ph.D., Senior Associate Dean for Research, School of Medicine Introduction
6:20 to 6:30 Laura Hays, Ph.D., Executive Director, Fanconi Anemia Research Fund Making a difference: the David Frohnmayer advocacy formula
6:30 to 6:35 Maureen Hoatlin, Ph.D.,MBA OHSU Rare Disease Consortium overview and objective of the symposium
6:35 to 6:45 Eric Orwoll, M.D. Osteogenesis imperfecta: a brittle bone disease with well-definedmolecular pathologies but limited clinical insights and therapies
6:45 to 6:55 David Sprio, M.D. A novel Real patient video platform that enables patients and clinicians to share rare disease phenotypes
6:55 to 7:05 Evan Shereck, M.D. Overview of the program in Pediatric Immunodeficiency Rare Disease Research Clinical Network
7:05 to 7:10 Markus Grompe, M.D. Program in Fanconi anemia
7:10 to 7:20 Cary Harding, M.D. Clinical Trials in inborn errrors of amino acid and fatty acid metabolism
7:20 to 7:40 David Ellison, M.D.
Part 1: All about that Bass: rare gene mutations and human blood pressure variation.
Part 2: How OCTRI can help rare disease research at OHSU
7:40 to 8:20 Xiaobing Quan, M.D., Ph.D Accelerating opportunities from discovery to clinic in rare disease research
8:20 to 8:25 Maureen Hoatlin, Ph.D, MBA Final Remarks, Action items, organizing for the future
8:25 to 8:30 iPad Giveaway